ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MNKD Stock Price » MNKD Stock News

Mannkind Share News

 Mannkind (mm) Stock Price
MNKD Stock Price
 Mannkind (mm) Stock Chart
MNKD Stock Chart
 Mannkind (mm) Stock News
MNKD Stock News
 Mannkind (mm) Company Information
MNKD Company Information
 Mannkind (mm) Stock Trades
MNKD Stock Trades

MannKind CEO: Still Plan To Launch Afrezza In 2011

By Peter Loftus Of DOW JONES NEWSWIRES MannKind Corp.'s (MNKD) chief executive said Tuesday the company still expects to launch its inhalable insulin product in 2011, despite Monday's decision by U.S. regulators not to approve the product at this time. The U.S. Food and Drug Administration sent MannKind a so-called "complete response letter" Friday asking for more information about Alfrezza, which MannKind hopes will become an alternative for diabetics who don't like injecting insulin. The news sent MannKind shares tumbling nearly 25% Monday, on fears that the FDA might never approve the product. But CEO Alfred Mann tried to reassure Wall Street in a conference call Tuesday morning, saying the agency asked for more information about how currently available data support the clinical utility of Afrezza in the marketplace. "We interpret this request as a desire to understand the positioning of Afrezza within the range of available therapies, and a desire to know how, and in whom, and when in the course of therapy it should be used," Mann said. MannKind shares rose 52 cents, or 6.6%, to $8.41 soon after the opening bell Tuesday. Mann said the company would discuss with the agency the "extensive efficacy data" that has already been submitted, as well as further analysis. Also, the FDA asked for information about the comparability of the commercial version of the MedTone inhaler device to the earlier version of this device that was used in clinical trials. Mann said the company plans to launch Afrezza with an even newer device, known as Dreamboat, and will seek FDA approval of that, which the company hopes will forestall significant delays. "At this point, we have no reason to believe that our plans to launch in 2011 are adversely impacted by issues raised in the...letter," Mann said. The FDA letter cited no safety concerns but requested updated safety data for the drug. The letter also requested changes to the proposed labeling of the cartridges, foil pouches and cartons. Mann said the letter didn't require any additional pre-marketing clinical studies to be conducted for the FDA to complete its review of the application. MannKind will request a meeting with the agency to discuss its approach for resolving the remaining issues. However, in cautionary language in MannKind's annual report filed Monday with the Securities and Exchange Commission, the company said the FDA could request that the company conduct additional clinical trials to provide sufficient data for approval. Mann said the receipt of the FDA letter could clear the way for negotiations with other companies to potentially market the product. The company is funded into early 2011 with "available financial resources," Mann said. An executive said this reflected existing cash and lines of credit. -Peter Loftus; Dow Jones Newswires; 215-656-8289; peter.loftus@dowjones.com

Stock News for Mannkind (MNKD)
DateTimeHeadline
07/18/201618:31:00Statement of Changes in Beneficial Ownership (4)
07/08/201617:00:00MannKind Corporation to Present at Cantor Fitzgerald’s 2nd A...
06/27/201608:25:00Biotechnology Equities at a Glance -- MannKind, bluebird bio...
06/12/201615:00:00MannKind Announces Late-Breaking Data Reinforcing Faster Onset...
06/10/201609:00:00MannKind Announces Collaboration with JDRF
05/24/201616:27:18Current Report Filing (8-k)
05/18/201608:02:16Statement of Changes in Beneficial Ownership (4)
05/18/201608:00:42Initial Statement of Beneficial Ownership (3)
05/10/201609:14:46Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
05/10/201608:40:25Current Report Filing (8-k)
05/09/201618:24:19MannKind Announces Pricing of Registered Direct Public Offering...
05/09/201616:46:04Current Report Filing (8-k)
05/09/201616:42:06Quarterly Report (10-q)
05/09/201616:00:00MannKind Corporation Reports 2016 First Quarter Financial Results
05/05/201617:00:00MannKind Corporation to Present at the Bank of America Merrill...
05/04/201617:33:47Current Report Filing (8-k)
05/04/201617:28:33Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
05/02/201617:00:00MannKind Corporation to Hold 2016 First Quarter Financial Results...
04/28/201606:01:26Notice of Effectiveness (effect)
04/26/201616:59:34Current Report Filing (8-k)

Mannkind and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad